Pressure Biosciences PBIO Stock News

Pressure BioSciences Inc (OTCMKTS: PBIO) is a stock that I’ve been following quite closely as of late. The company recently announced plans to move forward with a couple of acquisitions, bringing multiple products in the skincare and neutraceuticals space to the table.

Today, more news broke surrounding the company’s plans. Today, PBIO said that Jim Morrison has been appointed to serve as the new CEO of the rebranded public company. The implications here are massive:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

PBIO Stock Could Jump With Morrison In Charge

In the press release, Pressure BioSciences said that Jim Morrison will be in the lead position once the acquisitions and rebranding is complete. The new company, Availa Bio, will be greatly enhanced through a merger with Cannaworx and the acquisition of SkinScience Labs.

When it comes to who will lead the combined company, PBIO couldn’t have chosen a stronger suitor. Morrison has become a legend in the cosmetics industry, holding several leadership positions. For some time, he even held a position as President of L’Oreal.

Under his leadership, the household cosmetics brand grew more than 20% year over year on average. He’s also the brain behind the acquisitions of Redken and Matrix, leading to unprecedented growth.

Accross the industry, Mr. Morrison is known as a top brand strategist. In fact, Business Week Magazine once wrote:

Over the last two decades, Mr. Morrison has had a profound impact on the American Beauty Industry. In the industry’s history no other executive has had the level of financial responsibility or breadth of organizational experience as Jim. His devotion to, and success within the American Beauty Industry is unmatched.

In a statement, Jim Morrison, incoming CEO at PBIO upon the completion of proposed transactions, had the following to offer:

I have driven powerful growth across all traditional channels and moved companies into leadership positions in the beauty industry. I now have the opportunity to literally change the product development landscape of several major industries with the use of the UST Technology in the proliferation of new products that are expected to have greater bioavailability and efficacy than anything in the world today. I see Availa Bio as a transformational company. The chance to work with Drs. Bobby Ghalili and Adrienne Denese creates a dynamic synergy. My background in skin care, the incredible SkinScience brand, and my track record in launching new products into the market presents a very rare opportunity. Availa Bio will allow me to bring over 30 years of experience and my professional network to focus on revolutionary value creation for this powerful new entity.

This Is Massive News

The news here is incredible for Pressure BioSciences and all involved. Through the merger with Cannaworx, the company will be bringing several products to market over the next couple of years. One of which, has already seen incredible success, and with the recently launched neutraceutical to boost immune systems and the current COVID-19 pandemic, we could see a strong increase in revenue at the close of the merger.

Moreover, SkinScience Labs is already a massive brand, selling more than $500 million in skincare products to date. With the ex-President of L’Oreal taking the reins on the company’s product lineup, the sky is the limit.

All in all, with today’s news, PBIO should be paid close attention to.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Get Free Alerts

Join our free mailing list to receive stock alerts!

This website/newsletter is owned, operated and edited by CNA Finance, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” or “CNA Finance” refers to CNA Finance, LLC. This webpage/newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to publish information and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners do not own any shares in stocks mentioned unless stated in page disclosures. If we own any shares we will list the information relevant to the stock and number of shares here. CNA Finance, parent company to Alpha Stock News, receives payment to publish content and promote publicly traded companies. Pursuant to an agreement between CNA Finance and Pressure Biosciences, CNA Finance has been hired to develop and publicly disseminate information about PBIO via Websites and Email in exchange for one thousand five hundred dollars. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated digital outreach efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of digital outreach marketing, which may end as soon as the marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct and Pressure Biosciences has not approved the content of this site. Furthermore, CNA Finance often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.